Published in Cancer Res on January 01, 2005
Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest (2007) 8.65
Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med Genomics (2009) 1.55
Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation. Arterioscler Thromb Vasc Biol (2010) 1.23
A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol (2008) 1.09
Pathogenesis of ovarian cancer: clues from selected overexpressed genes. Future Oncol (2009) 1.08
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells. Cell Death Differ (2012) 1.05
Quantitative proteomic analysis by iTRAQ(R) for the identification of candidate biomarkers in ovarian cancer serum. Proteome Sci (2010) 1.02
Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer (2010) 0.99
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions. J Cell Mol Med (2011) 0.98
Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6Chigh monocytosis: evidence that the effects are not apolipoprotein E dependent. Circulation (2011) 0.98
Marine compounds selectively induce apoptosis in female reproductive cancer cells but not in primary-derived human reproductive granulosa cells. Mar Drugs (2012) 0.97
CancerMA: a web-based tool for automatic meta-analysis of public cancer microarray data. Database (Oxford) (2012) 0.95
Age, gender, and cancer but not neurodegenerative and cardiovascular diseases strongly modulate systemic effect of the Apolipoprotein E4 allele on lifespan. PLoS Genet (2014) 0.93
Direct Transcriptional Effects of Apolipoprotein E. J Neurosci (2016) 0.87
Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS One (2011) 0.85
Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for lung cancer: A marker phase I trial. Thorac Cancer (2014) 0.82
Roles of apolipoprotein E (ApoE) and inducible nitric oxide synthase (iNOS) in inflammation and apoptosis in preeclampsia pathogenesis and progression. PLoS One (2013) 0.76
The relationship between apolipoprotein E gene ε2/ε3/ε4 polymorphism and breast cancer risk: a systematic review and meta-analysis. Onco Targets Ther (2016) 0.76
Apolipoprotein E epsilon 2 allele and low serum cholesterol as risk factors for gastric cancer in a Chinese Han population. Sci Rep (2016) 0.76
Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer. BMC Cancer (2014) 0.76
Identification of Apolipoprotein C-I Peptides as a Potential Biomarker and its Biological Roles in Breast Cancer. Med Sci Monit (2016) 0.75
Apolipoprotein E4 Elicits Lysosomal Cathepsin D Release, Decreased Thioredoxin-1 Levels, and Apoptosis. J Alzheimers Dis (2016) 0.75
Inverse relationship between Alzheimer's disease and cancer, and other factors contributing to Alzheimer's disease: a systematic review. BMC Neurol (2016) 0.75
Association of the apolipoprotein E 2 allele with concurrent occurrence of endometrial hyperplasia and endometrial carcinoma. Oxid Med Cell Longev (2015) 0.75
Proteome mapping of epidermal growth factor induced hepatocellular carcinomas identifies novel cell metabolism targets and mitogen activated protein kinase signalling events. BMC Genomics (2015) 0.75
ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med (2010) 13.07
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science (2010) 10.78
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med (2010) 8.10
The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol (2010) 7.27
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol (2011) 5.53
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Ovarian cancer. Annu Rev Pathol (2009) 4.92
Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science (2004) 4.67
An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol (2009) 3.90
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
The role of chromosomal instability in tumor initiation. Proc Natl Acad Sci U S A (2002) 3.46
Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A (2004) 3.35
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma. Cancer (2005) 3.26
Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol (2008) 3.22
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res (2007) 3.07
Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol (2009) 2.94
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol (2005) 2.83
Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther (2006) 2.76
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res (2011) 2.71
Notch3 gene amplification in ovarian cancer. Cancer Res (2006) 2.66
Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol (2010) 2.65
The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer (2006) 2.61
Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol (2008) 2.60
MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60
Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med (2013) 2.58
Gene expression patterns in ovarian carcinomas. Mol Biol Cell (2003) 2.55
Three classes of genes mutated in colorectal cancers with chromosomal instability. Cancer Res (2004) 2.51
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol (2011) 2.41
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma. Proc Natl Acad Sci U S A (2005) 2.29
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. Hum Pathol (2012) 2.27
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26
Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res (2009) 2.25
Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol (2002) 2.18
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res (2005) 2.07
Endometrial safety and bleeding pattern during a five-year treatment with long-cycle hormone therapy. Menopause (2005) 2.03
Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol (2011) 2.03
Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res (2003) 2.01
Amplification of 11q13 in ovarian carcinoma. Genes Chromosomes Cancer (2008) 2.01
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions. J Pathol (2011) 1.94
Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology (2009) 1.91
Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst (2002) 1.90
Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res (2004) 1.89
Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology (2003) 1.86
Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81
Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78
The claudins. Genome Biol (2009) 1.76
Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med (2002) 1.72
DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res (2010) 1.71
Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases. Am J Surg Pathol (2009) 1.71
Amplicon profiles in ovarian serous carcinomas. Int J Cancer (2007) 1.70
The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Am J Surg Pathol (2007) 1.70
Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res (2004) 1.66
Light response of retinal ON bipolar cells requires a specific splice variant of Galpha(o). J Neurosci (2002) 1.62
Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res (2006) 1.62
PIK3CA mutations in advanced ovarian carcinomas. Hum Mutat (2005) 1.61
Increased plasma DNA integrity in cancer patients. Cancer Res (2003) 1.59
Digital karyotyping. Nat Protoc (2007) 1.58
Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor). Int J Gynecol Pathol (2003) 1.58
Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One (2011) 1.57
Quality of pathology reports for advanced ovarian cancer: are we missing essential information? An audit of 479 pathology reports from the EORTC-GCG 55971/NCIC-CTG OV13 neoadjuvant trial. Eur J Cancer (2010) 1.57
Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol (2011) 1.56
Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones. J Urol (2003) 1.55
Principle and applications of digital PCR. Expert Rev Mol Diagn (2004) 1.55